Abstract:
Five methods were developed for simultaneous determination of spiramycin adipate and
oxytetracycline-HCl and/or tetracycline-HCl in their pharmaceutical formulations. The first one was a
densitometric evaluation of thin-layer chromatograms using a mobile phase of methanol: Butanol:
Chloroform: Ammonia 1% (5:1:1:1, by volume). The plates were visualized under UV lamp at 254
nm where spots appeared at Rf
0.76, 0.30 and 0.37 for spiramycin adipate, oxytetracycline-HCl and
tetracycline-HCl, respectively. The chromatograms of the drugs were measured densitometrically at
240 nm for spiramycin adipate and at 350 nm for both oxytetracycline-HCl and tetracycline-HCl in
the range of 0.1-0.8 µg mL-1 and 0.1-1.0 µg mL-1, respectively. Likewise, the simultaneous estimation of the cited drugs was performed by four spectrophotometric methods. Method A was a
mean centering (MC) which provided spiramycin adipate determination at 232 nm t
oxytetracycline-HCl or tetracyclinea third derivative (3D) through which spiramycin adipate could be estimated at 256 nm while the
wavelength 281 nm was selected for oxytetracyclin
C was a derivative ratio (1DR) that was established to determine spiramycin adipate only in the
presence of oxytetracycline-HCl or tetracycline
dual wavelength (IDW) which allowed the determination of oxytetracycline
spiramycin adipate and up to 50% of its impurity tetracycline.
the concentration range of 5-70
oxytetracycline-HCl and tetracycline
to be in accordance with those given by reported methods. The validity of the methods was
evaluated according to ICH guidelines.
